January 2005
Worldwide Biotech;Jan2005, Vol. 17 Issue 1, p1
Trade Publication
Reports on the cooperation and option agreement signed by Biotie Therapies Corp. and Somaxon Pharmaceuticals Inc. on nalmefene in July 2004. Terms of the agreement; Amount of license fee to be paid by Somaxon to Biotie; Information on nalmefene.


Related Articles

  • SOMAXON REPORTS FIRST QTR 2009 NET LOSS OF $4.5 MILLION.  // Biotech Financial Reports;Jun2009, Vol. 16 Issue 6, p7 

    The article reports on the financial performance of Somaxon Pharmaceuticals Inc., a specialty pharmaceutical company in San Diego, California, during the first quarter ended March 31, 2009. The company has reported a net loss of $4.5 million. It has also posted a gain of $1 million in license...

  • The Week's Biggest Gainers and Losers.  // BioWorld Insight;10/15/2012, Vol. 20 Issue 42, p25 

    The article lists several pharmaceutical companies in the U.S. including Oxis International, Aveo Pharmaceuticals Inc. and Somaxon Pharmaceuticals Inc.

  • Somaxon Pharmaceuticals to Report Full Year and 4th qtr Ended Dec 31 2010 Financial Results and Conduct Conference Call on Thurs, March 3.  // Biomedical Market Newsletter;3/14/2011, p110 

    The article announces that San Diego, California-based pharmaceutical company Somaxon Pharmaceuticals Inc. will release its financial results for the 4th quarter ending December 31, 2010 following the closing of the U.S. financial markets. Furthermore, the company will host a conference call on...

  • Somaxon and Paladin Announce Silenor(r) Ex-US Collaboration.  // Biomedical Market Newsletter;6/9/2011, p137 

    The article reports on the collaboration of pharmaceutical companies Somaxon Pharmaceuticals Inc. and Paladin Labs Inc. regarding Paladin's commercialization of Silenor® (doxepin) drug for insomnia in Canada, South America and Africa. It says that Somaxon will receive 500,00 U.S dollars...

  • Somaxon Adding $26M; Sales Efforts for Silenor Under Way. Boggs, Jennifer // BioWorld Today;11/22/2010, Vol. 21 Issue 226, p2 

    The article reports on the 26 million dollar public offering launched by Somaxon Pharmaceuticals Inc. The offering will involve the sale of the company's 8.8 million shares valued at 2.95 dollars per share. Proceeds from the transaction will be used to support the company's commercialization...

  • Sleep Disorder Update.  // PharmaWatch: CNS;Feb2007, Vol. 6 Issue 2, p5 

    The article offers news briefs related to the development of drugs by pharmaceutical industry in the U.S. Somaxon Pharmaceuticals Inc. succeed in its phase III clinical trial of Silenor for insomnia. Neurogen Corp. started the phase II clinical trial for NG2-73, a medicine for chronic insomnia...

  • Somaxon: Silenor data offers promise, but generic challenge awaits.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p11 

    The article discusses the results of the phase III clinical study of Sinelor, an experimental drug candidate of Somaxon Pharmaceuticals Inc. for the treatment of insomnia, which suggest that it is effective and safe in adults with primary insomnia. The data, which were presented at the American...

  • IPO Ahead. Weeks, Katie // San Diego Business Journal;10/17/2005, Vol. 26 Issue 42, p50 

    Reports that Somaxon Pharmaceuticals Inc. has filed to go public with the U.S. Securities and Exchange Commission.

  • Corporate News Update.  // PharmaWatch: CNS;Mar2011, Vol. 10 Issue 3, p22 

    The article offers news briefs related to pharmaceutical industry. Drug delivery company IntelGenx Corp. has reported that its patent lawsuit charged by Biovail Laboratories International SLR was dismissed by the U.S. District Court of Delaware. BioClinica Inc. has partnered with specialty...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics